Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Denali Therapeutics Inc. on January 11, 2021, reporting events occurring on January 8, 2021. The filing addresses corporate governance changes and regulatory disclosures regarding program updates.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Compensation: $40,000 for the new director.
- Initial Equity Grant Value: Approximately $600,000 (split 60% stock options, 40% RSUs).
- Standard Annual Equity Grant Value: Approximately $350,000 for continuing non-employee directors.
Material Changes
The primary material change is the appointment of Nancy Thornberry to the Board of Directors as a Class I director, effective January 8, 2021. Her term expires at the 2021 annual meeting of stockholders. Additionally, the Company issued a press release updating its program milestones for 2021 and confirming participation in the JP Morgan Healthcare Conference.
Guidance, Outlook, and Risks
The Company issued a press release (Exhibit 99.2) detailing expected milestones for 2021 and program updates. The filing explicitly states that the information in the press releases is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific risks or contingencies are detailed within the text of this 8-K, other than standard vesting conditions for equity awards.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.2) for specific details on 2021 program milestones and clinical updates.
- Verify the vesting schedule for the new director's equity awards (25% at one year, monthly thereafter for options; annual tranches for RSUs).
- Confirm the Company's participation schedule at the JP Morgan Healthcare Conference.
- Check subsequent filings for the formal financial results for the period ending December 31, 2020, as this 8-K does not contain them.